BCLI - BrainStorm Cell Therapeutics GAAP EPS of -$0.66 misses by $0.52
2023-03-30 07:06:47 ET
- BrainStorm Cell Therapeutics press release ( NASDAQ: BCLI ): Q4 GAAP EPS of -$0.66 misses by $0.52 .
- Cash, cash equivalents, and short-term bank deposits were approximately $3 million as of December 31, 2022, compared to $22 million as of December 31, 2021.
For further details see:
BrainStorm Cell Therapeutics GAAP EPS of -$0.66 misses by $0.52